Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS AGAINST OFFICERS AND DIRECTORS OF ACTINIUM PHARMACEUTICALS, INC. (NYSE: ANTM)

Grabar Law Office is investigating whether the Board of Directors of Actinium Pharmaceuticals, Inc. (NYSE: ANTM) breached their fiduciary duties owed to the Company.

Current Actinium Pharmaceuticals, Inc. (NYSE: ANTM) shareholders who have held the stock since on or before October 31, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.  Contact Joshua H. Grabar at [email protected], or call 267-507-6085 to learn more.

WHY: An underlying securities fraud class action complaint alleges that Actinium Pharmaceuticals, Inc. (NYSE: ANTM), through certain of its officers, made materially false and misleading statements that conditioned investors to believe that there was a very high likelihood that the Food and Drug Administration ("FDA") would review and approve Actinium's Biologics License Application ("BLA") for Iomab-B. Specifically, Defendants (1) repeatedly touted the Phase 3 Sierra trial's (the "Sierra Trial") positive Complete Remission ("DCR") data while downplaying the study's failure to generate statistically significant or clinically meaningful Overall Survival data; and (2) misled investors about the importance of the Sierra Trial's poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the Biologics License Application ("BLA").

WHAT TO DO NOW: Current Actinium shareholders who have held Actinium shares since on or before October 31, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.

If you would like to learn more about this matter, please contact Joshua H. Grabar at [email protected] or call 267-507-6085.

Please enter your name.
Please enter a valid phone number.
Please enter a message.
Send

                                                                                           Attorney Advertising Disclaimer

Standard Derivative Form Retainer

Standard Form Derivative Retainer Letter - No Cost

  • Join This Action

  • Alternatively, you may upload your transactions using the upload button below or email them to [email protected]. *

  • Drop files here or
    Max. file size: 100 MB.
    • Clear Signature
      Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

    • Date of signing: *

    • MM slash DD slash YYYY
    • This field is for validation purposes and should be left unchanged.